Welcome to our dedicated page for Vistagen Therapeutics news (Ticker: VTGN), a resource for investors and traders seeking the latest updates and insights on Vistagen Therapeutics stock.
Vistagen Therapeutics, Inc. develops late clinical-stage biopharmaceutical programs based on nose-to-brain neurocircuitry and intranasal pherine product candidates. Company news centers on fasedienol nasal spray for the acute treatment of social anxiety disorder, including PALISADE Phase 3 study updates, and refisolone nasal spray for vasomotor symptoms due to menopause.
Recurring updates also cover FDA and IND communications, clinical data from psychiatric and neurological programs, fiscal results, cash-management actions, executive and board changes, and healthcare investor conference presentations. The company’s pipeline is described around investigational intranasal candidates for indications that include social anxiety disorder, major depressive disorder, and menopausal hot flashes.
VistaGen Therapeutics (NASDAQ: VTGN) has scheduled a conference call for June 23, 2022, at 2:00 PM PT to discuss its fiscal year 2022 financial results, ending March 31, 2022. The call will also cover recent achievements and future milestones. The company is focused on advancing therapeutics for anxiety and depression, particularly its lead candidate, PH94B, a nasal spray currently in Phase 3 trials in the U.S. Results are expected in 2022. If successful, PH94B could become the first FDA-approved rapid treatment for social anxiety.
VistaGen Therapeutics, Inc. (Nasdaq: VTGN) announced the acceptance of an abstract for its Phase 2A clinical trial studying PH94B, a rapid-onset nasal spray for anxiety disorders, at the ASCP Annual Meeting from May 31 to June 3, 2022. The trial focuses on adjustment disorder with anxiety (AjDA), aiming to evaluate efficacy and safety. PH94B is noted for its unique mechanism, intended to offer rapid relief from anxiety symptoms. CEO Shawn Singh emphasized the increasing mental health challenges and the demand for innovative treatments amidst this urgent need.
VistaGen Therapeutics (Nasdaq: VTGN) announced participation in two upcoming investor conferences in June: the William Blair 42nd Annual Growth Stock Conference on June 7 at 2:00 PM CT in Chicago, and the Jefferies Global Healthcare Conference on June 9 at 10:00 AM ET in New York. CEO Shawn Singh will engage in discussions aimed at transforming treatment for anxiety and depression. The company’s lead candidate, PH94B, is positioned to be a leading fast-acting treatment for social anxiety disorder, currently undergoing Phase 3 trials in the U.S.
VistaGen Therapeutics (Nasdaq: VTGN) announced that the FDA confirmed there is no signal of abuse potential for its investigational treatment PH94B, designed for acute treatment of adults with social anxiety disorder (SAD). Based on completed clinical and nonclinical data, the FDA stated additional studies to assess abuse potential are unnecessary, and a human abuse potential study is not needed at this time. VistaGen is advancing PH94B through its Phase 3 PALISADE program. With over 25 million affected in the U.S., effective treatment options are critical for those suffering from SAD.
VistaGen Therapeutics (Nasdaq: VTGN) has appointed Reid Adler as its new Chief Legal Officer. Adler brings over three decades of legal experience and has previously served as outside counsel for the company. He will oversee legal affairs and provide strategic guidance to VistaGen’s Executive Team and Board. CEO Shawn Singh expressed confidence in Adler's leadership, emphasizing the company's commitment to transforming mental health treatment. VistaGen focuses on advancing therapeutics for anxiety and depression, aiming to launch faster-acting treatments with fewer side effects.
VistaGen Therapeutics (Nasdaq: VTGN) announced the presentation of preclinical data at significant scientific meetings, emphasizing the unique mechanism of action (MOA) of their candidate PH94B, aimed at treating social anxiety disorder (SAD). Notably, PH94B's anxiolytic properties do not require systemic uptake, reducing side effect risks. Researchers will showcase findings on April 30 and during the ASCP meeting in June 2022. VistaGen is currently conducting Phase 3 trials for PH94B, seeking to address the rising mental health crisis effectively.
VistaGen Therapeutics (NASDAQ: VTGN) and AffaMed Therapeutics have completed regulatory preparations for the PALISADE Global Phase 3 clinical trial of PH94B. This trial will assess the efficacy, safety, and tolerability of PH94B, a nasal spray, for treating social anxiety disorder (SAD) in adults. Expected to initiate in the second half of 2022, the trial aims to support commercialization in China and other markets outside the U.S. The trial design is based on previous PALISADE studies, with initial results anticipated by mid-2024.
VistaGen Therapeutics (Nasdaq: VTGN), a biopharmaceutical company focused on CNS disorders, announced that CEO Shawn Singh will participate in a fireside chat with Maxim Analyst Jason McCarthy on March 28, 2022, at 2:00 p.m. PT during the Maxim Group 2022 Virtual Growth Conference. In addition, a recorded corporate presentation highlighting its pipeline and milestones will be available to registered attendees from March 28, 2022, 6:00 a.m. PT. VistaGen is developing PH94B, a nasal spray for acute anxiety treatment, currently in Phase 3 trials.
VistaGen Therapeutics (Nasdaq: VTGN) reports progress in its late-stage clinical programs for PH94B, targeting social anxiety disorder (SAD), with topline data from PALISADE-1 and PALISADE-2 trials expected in mid-2022 and the second half of 2022, respectively. The company has initiated the PALISADE Long-term Safety Study and a Phase 2A trial for adjustment disorder with anxiety (AjDA). Additionally, a Phase 2B study for PH10 in major depressive disorder (MDD) is set to commence in late 2022. The net loss for Q3 2022 was approximately $10.5 million, with cash reserves of $83.7 million as of December 31, 2021.
VistaGen Therapeutics (NASDAQ: VTGN) announced a conference call scheduled for February 10, 2022, at 2:00 PM PT to discuss its financial results for the third quarter of fiscal year 2022, which ended December 31, 2021. The call aims to review recent accomplishments and outline upcoming milestones for the company, focusing on its commitment to developing innovative medicines for CNS disorders. A live audio webcast will be accessible, and a recorded playback will be available afterward.